Excellent
Fully Aligned
Patient Risk:
Low
Summary
The claim is fully supported by SOVALDI labeling for HBV reactivation risk: it matches the label’s directed testing (HBsAg and anti-HBc prior to initiation), monitoring during and after treatment, and need for appropriate management if reactivation/hepatitis flare occurs.
Category Scores
Accurate Statements
For patients coinfected with HCV and HBV, HBV reactivation risk should be assessed by testing for HBV evidence before starting SOVALDI (HBsAg and anti-HBc).
Label (5.1, 2.1) directs testing all patients for evidence of current or prior HBV infection using HBsAg and anti-HBc before initiating HCV treatment with SOVALDI.
Patients should be monitored during SOVALDI treatment and during post-treatment follow-up for clinical and laboratory signs of hepatitis flare or HBV reactivation.
Label (5.1) instructs monitoring during HCV treatment and during post-treatment follow-up in patients with serologic evidence of HBV infection.
Appropriate patient management should be initiated if HBV reactivation or hepatitis flare occurs.
Label (5.1) states to initiate appropriate patient management for HBV infection as clinically indicated.
HBV reactivation can occur during or after treatment of HCV infection, and patients should be informed to report a history of HBV infection.
Label (17) informs that HBV reactivation can occur during or after treatment and advises patients to tell their healthcare provider if they have a history of HBV infection.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim matches on-label risk mitigation steps (pre-treatment testing, monitoring during and after treatment, and management as clinically indicated) for the labeled HBV reactivation risk in HCV/HBV coinfected patients.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement